The U.S. Food and Drug Administration (FDA) on Monday announced the approval of Biogen’s human monoclonal antibody Aduhelm (aducanumab) for use in patients with Alzheimer’s disease under the agency’s ...

A US Food and Drug Administration (FDA) official who oversaw the approval of the controversial Alzheimer's therapy aducanumab (Aduhelm) is retiring from the agency to 'explore other opportunities.' ...

The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...

On Monday, the US Food and Drug Administration granted approval to a keenly-watched Alzheimer’s drug, aducanumab, developed by the drugmaker Biogen. The decision to approve the drug, which was once ...

The Food and Drug Administration approved the drug aducanumab to treat patients with Alzheimer's disease on Monday. It is the first new drug approved by the agency for Alzheimer's disease since 2003.

With FDA approval, aducanumab is certain to be covered by virtually all insurers, including Medicare, the government plan for seniors that covers more than 60 million people. Both the FDA and Medicare ...

Patients and their families are starting to inquire about the new Alzheimer's drug approved this week by the US Food and Drug Administration. Shipments of the medication are expected to go out in just ...